Podcast
Questions and Answers
Which of the following CAR T-cell therapies targets the BCMA antigen?
Which of the following CAR T-cell therapies targets the BCMA antigen?
- Brexucabtagene autoleucel
- Idecabtagene vicleucel (correct)
- Lisocabtagene maraleucel
- Axicabtagene ciloleucel
A patient with relapsed/refractory follicular lymphoma after two or more lines of therapy might be considered for treatment with which of the following?
A patient with relapsed/refractory follicular lymphoma after two or more lines of therapy might be considered for treatment with which of the following?
- Ciltacabtagene autoleucel
- Blinatumomab
- Tisagenlecleucel
- Axicabtagene ciloleucel (correct)
Which of the following bispecific T-cell engagers is approved for relapsed/refractory follicular lymphoma?
Which of the following bispecific T-cell engagers is approved for relapsed/refractory follicular lymphoma?
- Mosunetuzumab (correct)
- Elranatamab
- Talquetamab
- Teclistamab
A young adult (22 years old) is diagnosed with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). Which CAR T-cell therapy is most appropriate?
A young adult (22 years old) is diagnosed with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). Which CAR T-cell therapy is most appropriate?
Which of the following therapies is a bispecific T-cell engager targeting BCMA and CD3?
Which of the following therapies is a bispecific T-cell engager targeting BCMA and CD3?
Which therapy is indicated for relapsed/refractory B-cell precursor acute lymphoblastic leukemia with minimal residual disease?
Which therapy is indicated for relapsed/refractory B-cell precursor acute lymphoblastic leukemia with minimal residual disease?
A patient with relapsed/refractory multiple myeloma who has already undergone four or more lines of therapy, including an IMiD, PI, and anti-CD38 mAb, would be eligible for which of the following CAR T-cell therapies?
A patient with relapsed/refractory multiple myeloma who has already undergone four or more lines of therapy, including an IMiD, PI, and anti-CD38 mAb, would be eligible for which of the following CAR T-cell therapies?
A patient with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of therapy may be treated with:
A patient with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of therapy may be treated with:
Which of the following CAR T-cell therapies is NOT indicated for relapsed/refractory large B-cell lymphoma (LBCL)?
Which of the following CAR T-cell therapies is NOT indicated for relapsed/refractory large B-cell lymphoma (LBCL)?
What is the target of Brexucabtagene autoleucel?
What is the target of Brexucabtagene autoleucel?
Flashcards
Tisagenlecleucel (Kymriah)
Tisagenlecleucel (Kymriah)
Targets CD19 and uses CAR T-cell therapy. Used for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) in patients up to 25 years and relapsed/refractory large B-cell lymphoma (LBCL) after 2+ lines of therapy.
Axicabtagene ciloleucel (Yescarta)
Axicabtagene ciloleucel (Yescarta)
Targets CD19 and uses CAR T-cell therapy. Used for relapsed/refractory large B-cell lymphoma (LBCL) after 2+ lines of therapy and relapsed/refractory follicular lymphoma (FL) after 2+ lines of therapy.
Brexucabtagene autoleucel (Tecartus)
Brexucabtagene autoleucel (Tecartus)
Targets CD19 and uses CAR T-cell therapy. Used for relapsed/refractory mantle cell lymphoma (MCL) and relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) in adults.
Lisocabtagene maraleucel (Breyanzi)
Lisocabtagene maraleucel (Breyanzi)
Signup and view all the flashcards
Idecabtagene vicleucel (Abecma)
Idecabtagene vicleucel (Abecma)
Signup and view all the flashcards
Ciltacabtagene autoleucel (Carvykti)
Ciltacabtagene autoleucel (Carvykti)
Signup and view all the flashcards
Blinatumomab (Blincyto)
Blinatumomab (Blincyto)
Signup and view all the flashcards
Teclistamab (Tecvayli)
Teclistamab (Tecvayli)
Signup and view all the flashcards
Elranatamab (Elrexfio)
Elranatamab (Elrexfio)
Signup and view all the flashcards
Talquetamab (Talvey)
Talquetamab (Talvey)
Signup and view all the flashcards
Study Notes
- Study notes on CART and Bi-specific T-cell Engager therapies.
Tisagenlecleucel (Kymriah)
- Targets CD19 using CAR T-cell therapy.
- Indicated for relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) in patients up to 25 years.
- Indicated for relapsed or refractory large B-cell lymphoma (LBCL) after 2+ lines of therapy.
Axicabtagene ciloleucel (Yescarta)
- Targets CD19 using CAR T-cell therapy.
- Indicated for relapsed/refractory large B-cell lymphoma (LBCL) after 2+ lines of therapy.
- Indicated for relapsed/refractory follicular lymphoma (FL) after 2+ lines of therapy.
Brexucabtagene autoleucel (Tecartus)
- Targets CD19 using CAR T-cell therapy.
- Indicated for relapsed or refractory mantle cell lymphoma (MCL).
- Indicated for relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) in adults.
Lisocabtagene maraleucel (Breyanzi)
- Targets CD19 using CAR T-cell therapy.
- Indicated for relapsed or refractory large B-cell lymphoma (LBCL) after 1+ lines of therapy.
- Indicated for relapsed or refractory follicular lymphoma (FL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after specific prior therapies.
Idecabtagene vicleucel (Abecma)
- Targets BCMA using CAR T-cell therapy.
- Indicated for relapsed or refractory multiple myeloma (MM) after 4+ lines of therapy including an IMiD, PI, and anti-CD38 mAb.
Ciltacabtagene autoleucel (Carvykti)
- Targets BCMA using CAR T-cell therapy.
- Indicated for relapsed/refractory multiple myeloma (MM) after 4+ lines of therapy including an IMiD, PI, and anti-CD38 mAb.
Blinatumomab (Blincyto)
- Targets CD19/CD3 using Bispecific T-cell engager.
- Indicated for relapsed/refractory B-cell precursor acute lymphoblastic leukemia (B-ALL).
- Also indicated for B-ALL with minimal residual disease (MRD).
Teclistamab (Tecvayli)
- Targets BCMA/CD3 using Bispecific T-cell engager.
- Indicated for relapsed or refractory multiple myeloma (MM) after 4+ lines of therapy including an IMiD, PI, and anti-CD38 mAb.
Elranatamab (Elrexfio)
- Targets BCMA/CD3 using Bispecific T-cell engager.
- Indicated for relapsed/refractory multiple myeloma (MM) after 4+ lines of therapy including an IMiD, PI, and anti-CD38 mAb.
Talquetamab (Talvey)
- Targets GPRC5D/CD3 using Bispecific T-cell engager.
- Indicated for relapsed or refractory multiple myeloma (MM) after 4+ lines of therapy including an IMiD, PI, and anti-CD38 mAb.
Mosunetuzumab (Lunsumio)
- Targets CD20/CD3 using Bispecific T-cell engager.
- Indicated for relapsed/refractory follicular lymphoma (FL) after 2+ lines of therapy.
Glofitamab (Columvi)
- Targets CD20/CD3 using Bispecific T-cell engager.
- Indicated for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after 2+ lines of therapy.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
